Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth.

Remacle AG, Golubkov VS, Shiryaev SA, Dahl R, Stebbins JL, Chernov AV, Cheltsov AV, Pellecchia M, Strongin AY.

Cancer Res. 2012 May 1;72(9):2339-49. doi: 10.1158/0008-5472.CAN-11-4149. Epub 2012 Mar 9.

2.

Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9.

Dufour A, Sampson NS, Li J, Kuscu C, Rizzo RC, Deleon JL, Zhi J, Jaber N, Liu E, Zucker S, Cao J.

Cancer Res. 2011 Jul 15;71(14):4977-88. doi: 10.1158/0008-5472.CAN-10-4552. Epub 2011 Jun 6. Erratum in: Cancer Res. 2012 Oct 1;72(19):5141-2. Dosage error in article text.

3.

Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.

Remacle AG, Shiryaev SA, Radichev IA, Rozanov DV, Stec B, Strongin AY.

J Biol Chem. 2011 Jun 10;286(23):21002-12. doi: 10.1074/jbc.M110.200139. Epub 2011 Apr 25.

4.

Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain.

Basu B, Correa de Sampaio P, Mohammed H, Fogarasi M, Corrie P, Watkins NA, Smethurst PA, English WR, Ouwehand WH, Murphy G.

Int J Biochem Cell Biol. 2012 Feb;44(2):393-403. doi: 10.1016/j.biocel.2011.11.015. Epub 2011 Nov 26.

PMID:
22138224
6.

The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice.

Ezhilarasan R, Jadhav U, Mohanam I, Rao JS, Gujrati M, Mohanam S.

Int J Cancer. 2009 Jan 15;124(2):306-15. doi: 10.1002/ijc.23951.

7.

Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration.

Cao J, Kozarekar P, Pavlaki M, Chiarelli C, Bahou WF, Zucker S.

J Biol Chem. 2004 Apr 2;279(14):14129-39. Epub 2004 Jan 16.

8.

CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain.

Mori H, Tomari T, Koshikawa N, Kajita M, Itoh Y, Sato H, Tojo H, Yana I, Seiki M.

EMBO J. 2002 Aug 1;21(15):3949-59.

9.

The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist.

Roeb E, Schleinkofer K, Kernebeck T, Pötsch S, Jansen B, Behrmann I, Matern S, Grötzinger J.

J Biol Chem. 2002 Dec 27;277(52):50326-32. Epub 2002 Oct 15.

10.

Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.

Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ, Munshi HG.

Cancer Res. 2011 Feb 1;71(3):1019-28. doi: 10.1158/0008-5472.CAN-10-1855. Epub 2010 Dec 8.

11.
12.

Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration.

Zarrabi K, Dufour A, Li J, Kuscu C, Pulkoski-Gross A, Zhi J, Hu Y, Sampson NS, Zucker S, Cao J.

J Biol Chem. 2011 Sep 23;286(38):33167-77. doi: 10.1074/jbc.M111.256644. Epub 2011 Jul 27.

13.

Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain.

Kothapalli R, Khan AM, Basappa, Gopalsamy A, Chong YS, Annamalai L.

PLoS One. 2010 Aug 31;5(8):e12494. doi: 10.1371/journal.pone.0012494.

14.

Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical.

Nisato RE, Hosseini G, Sirrenberg C, Butler GS, Crabbe T, Docherty AJ, Wiesner M, Murphy G, Overall CM, Goodman SL, Pepper MS.

Cancer Res. 2005 Oct 15;65(20):9377-87.

17.

Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase.

Li XY, Ota I, Yana I, Sabeh F, Weiss SJ.

Mol Biol Cell. 2008 Aug;19(8):3221-33. doi: 10.1091/mbc.E08-01-0016. Epub 2008 May 21.

18.
19.

Intradomain cleavage of inhibitory prodomain is essential to protumorigenic function of membrane type-1 matrix metalloproteinase (MT1-MMP) in vivo.

Golubkov VS, Chernov AV, Strongin AY.

J Biol Chem. 2011 Sep 30;286(39):34215-23. doi: 10.1074/jbc.M111.264036. Epub 2011 Aug 8.

20.

Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase.

Lehti K, Lohi J, Juntunen MM, Pei D, Keski-Oja J.

J Biol Chem. 2002 Mar 8;277(10):8440-8. Epub 2002 Jan 4.

Supplemental Content

Support Center